Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus

Vento, Sandro; Cainelli, Francesca; Mirandola, F.; Perri, Giampaolo; Solbiati, M; Concia, Ercole; Cosco, Lucio; Ferraro, Teresa

doi:10.1016/s0140-6736(96)90212-3

Cited by 158 publications

(92 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5][6][7]12 In contrast, in our patient, liver enzyme abnormalities was noted during the chemotherapy period and this implied to us drug related hepatotoxicity. However, liver biopsy and virological tests indicated HCV-related liver injury.…”

Section: Discussioncontrasting

confidence: 61%

“…[2][3][4][5]9 Also, there are only two case reports in the literature that evaluate the effect of chemotherapy for Hodgkin's lymphoma on concurrent HCV infection. 5,9 In the first report, Vento et al 5 described a patient receiving ABVD chemotherapy for Hodgkin's disease. At the end of chemotherapy, serum HCV-RNA level was very high (10 8 copy/mL).…”

Section: Discussionmentioning

confidence: 99%

“…[11][12][13][14] Reports on hepatitis C exacerbation related to the use of ABVD regimen, as in our case, are scarce. 5 Presence of active hepatitis, HBV coinfection and corticosteroid treatment are defined as risk factors for HCV-related liver injury. 6 The standard treatment for chronic hepatitis C is the combined use of pegylated interferon-alpha (Peg-IFN-α) and ribavirin for 48 weeks in viral genotype 1, and 24 weeks in genotype 2 and 3.…”

Section: Discussionmentioning

confidence: 99%

“…Data on the consequence of chemotherapy on the course of HCV infection in those patients have been controversial, and most of them are related to NHL. [5][6][7][8][9][10][11] Owing to the rare concurrence of HCV infection and Hodgkin's lymphoma, there are scarce published data on the effects of chemotherapy regimens on the course of HCV infection. 5,9 Furthermore, treatment and long term follow-up data of HCV infection in such patients are unavailable.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Hepatitis C Virus Related Liver Dysfunction During Chemotherapy for Hodgkin’s Lymphoma

Erol¹

2012

UHOD

View full text Add to dashboard Cite

Concurrent Hodgkin's lymphoma and Hepatitis C virus (HCV) infection is a rare clinical condition. Also, HCV related liver dysfunction during lymphoma chemotherapy is uncommon and most data come from patients with non-Hodgkin's lymphoma. We reported here a case of HCV related liver dysfunction during chemotherapy for Hodgkin's lymphoma and long term follow-up results of the patient, and we reviewed the literature.Keywords: Hepatitis C, Infection, Liver dysfunction, Lymphoma ÖZET Hodgkin Lenfoma Kemoterapisi S›ras›nda Ortaya Ç›kan Hepatit C Virusu ile ‹liflkili Karaci¤er DisfonksiyonuHodgkin lenfoma ve Hepatitis C virus (HCV) infeksiyonu birlikteli¤i nadir bir klinik durumdur. Ayr›ca, lenfoma kemoterapisi esnas›nda ortaya ç›kan HCV reaktivasyonu da s›k karfl›lafl›lmayan bir durum olup, bu konudaki verilerin ço¤u da non-Hodgkin lenfomal› hastalardan gelmektedir. Biz burada Hodgkin lenfoma kemoterapisi s›ras›nda ortaya ç›kan HCV'ye ba¤l› bir karaci¤er disfonksiyonu olgusunu, bu olgunun uzun süreli sonuçlar›n› sunduk ve bu konudaki literatürü irdeledik

show abstract

Section: Discussioncontrasting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hepatitis C Virus Related Liver Dysfunction During Chemotherapy for Hodgkin’s Lymphoma

Erol¹

2012

UHOD

View full text Add to dashboard Cite

show abstract

“…In French series [8], there is a worse overall survival among HCV-positive patients partly due to the increased incidence of hepatic toxicity among these patients, leading to three deaths of 24 HCV-positive patients [8]. Two cases of HCV-related fulminant hepatitis following chemotherapy had been previously reported in the literature [19].…”

Section: Discussionmentioning

confidence: 99%

Impact of treatment‐related liver toxicity on the outcome of HCV‐positive non‐Hodgkin's lymphomas

et al. 2009

View full text Add to dashboard Cite

We studied 160 Hepatitis C virus (HCV)-positive patients with NHL (59 indolent NHL, 101 aggressive). Median age was 67 years. HCV-RNA was present in 146. HBsAg was positive in seven patients. At diagnosis, ALT value was above UNL in 67 patients. One hundred and twenty patients received an anthracycline-based therapy, alkylators, 28 received chemotherapy plus rituximab. Cytotoxic drugs dose was reduced in 63 patients. Among 93 patients with normal ALT at presentation, 16 patients developed WHO grade II-III liver toxicity. Among 67 patients with abnormal ALT, eight patients had a 3.5 times elevation during treatment. Among 28 patients treated with rituximab and chemotherapy, five patients (18%) developed liver toxicity. Thirty four patients (21%) did not complete treatment (eight for liver toxicity). Median progression-free survival (PFS) for patients who experienced liver toxicity is significantly shorter than median PFS of patients without toxicity (respectively, 2 years and 3.7 years, P 5 0.03). After a median F-UP of 2 years, 32 patients died (three for hepatic failure). A significant proportion of patients with HCV1 NHL develop liver toxicity often leading to interruption of treatment. This could be a limit to the application of immunochemotherapy programs. HCV1 lymphomas represent a distinct clinical subset of NHL that deserves specific clinical approach to limit liver toxicity and ameliorate survival. Am. J. Hematol. 85:46-50, 2010. V

show abstract

Follow-up of four HIV-infected individuals after administration of hepatitis C virus and GBV-C/hepatitis G virus contaminated intravenous immunoglobulin: Evidence for HCV but not for GBV-C/HGV transmission

Berger

Scharrer²,

Weber

1997

J. Med. Virol.

View full text Add to dashboard Cite

In 1994, hepatitis C virus (HCV) infection was transmitted to four HIV seropositive patients attending the Department of Angiology, University Clinics, Frankfurt am Main, by the administration of Gammagard. The patients were suffering from thrombocytopenia and received betweeen 20 and 30 g of the contaminated lot 93F21AB11. GBV-C/HGV RNA could be amplified from the Gammagard lot 93F21AB11 using 5'NCR and NS5 primer pairs. All the four patients were negative in the GBV-C/HGV RT-PCR prior to therapy and until the end of the follow-up period. GBV-C/HGV IgG antibodies to the putative envelope (E2) were detected using the E2 HGV-env kit (Boehringer-Mannheim, Germany) in Gammagard lot 93F21AB11 and in one patient before donation of immunoglobulin. Anti-E2 seroconversion was observed in one recipient, the other two patients remained anti-E2 seronegative until the end of the observation period. It is concluded that there is no direct evidence for transmission of GBV-C/HGV by contaminated intravenous immunoglobulin since GBV-C/HGV RNA was not detected in the recipients up to 1 year after administration.

show abstract

Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus

Cited by 158 publications

References 8 publications

Hepatitis C Virus Related Liver Dysfunction During Chemotherapy for Hodgkin’s Lymphoma

Hepatitis C Virus Related Liver Dysfunction During Chemotherapy for Hodgkin’s Lymphoma

Impact of treatment‐related liver toxicity on the outcome of HCV‐positive non‐Hodgkin's lymphomas

Follow-up of four HIV-infected individuals after administration of hepatitis C virus and GBV-C/hepatitis G virus contaminated intravenous immunoglobulin: Evidence for HCV but not for GBV-C/HGV transmission

Contact Info

Product

Resources

About